DV
Dividend Vision

PYPD — PolyPid

PolyPid (PYPD)

Total return is -99.2% over the past 6.1 years, 280.2 points behind SPY at 181.0%. Its deepest 1-year drawdown was 33.0%.

PolyPid Ltd. is a biopharmaceutical company developing targeted, locally administered therapeutics using its proprietary polymer-lipid encapsulation matrix technology, with its lead candidate D-PLEX100 in Phase 3 trials for preventing surgical site infections and OncoPLEX in preclinical development for cancer treatment. The company does not currently distribute dividends. PolyPid appeals primarily to investors seeking exposure to clinical-stage biotech development rather than current income.

PYPD key facts

Asset type
Stock
Asset class
Equity
Inception date
06/26/2020
Last close
$4.74
Market cap
$71,711,048
Average volume
57900.0
Beta
1.4
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.27